Ocean Biomedical (Ocean Biomedical) Accounts Receivable : $0.00 Mil (As of Sep. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Ocean Biomedical Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Ocean Biomedical's accounts receivables for the quarter that ended in Sep. 2023 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Ocean Biomedical's Net-Net Working Capital per share for the quarter that ended in Sep. 2023 was $-2.24.

Ocean Biomedical Accounts Receivable Historical Data

The historical data trend for Ocean Biomedical's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocean Biomedical Accounts Receivable Chart

Ocean Biomedical Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Accounts Receivable

Ocean Biomedical Quarterly Data
	Dec19	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Accounts Receivable	Get a 7-Day Free Trial										-	-	-	-	-

Ocean Biomedical Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Ocean Biomedical Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Ocean Biomedical's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Ocean Biomedical's accounts receivable are only considered to be worth 75% of book value:

Ocean Biomedical's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(0.031	+	0.75 * 0	+	0.5 * 0	-	76.255
-	0	-	0)	/	34.0872
=	-2.24

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Ocean Biomedical Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Ocean Biomedical's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocean Biomedical (Ocean Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocean Biomedical Inc (NAS:OCEA) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

8AW0:Germany

Address

55 Claverick Street, Room 325, Providence, RI, USA, 02903

Website

https://www.oceanbiomedical.com

Ocean Biomedical Inc is a biopharmaceutical company. It is dedicated towards partnering with inventor-scientists and research institutes to bridge the gap between basic research and clinical development, to get new medicines to the patients who need it most.

Executives

Robert J Sweeney	officer: Chief Accounting Officer	20298 CRAIGEN CIRCLE, SARATOGA CA 95070
M Michelle Berrey	director	303A COLLEGE ROAD EAST, PRINCETON NJ 08450
William F Owens	director	C/O KEY ENERGY SERVICES, INC., 1301 MCKINNEY STREET, SUITE 1800, HOUSTON TX 77010
Inderjote S Kathuria	officer: Chief Strategy Officer	19W060 AVENUE LATOUR, OAK BROOK IL 60523
Gurinder S Kalra	officer: Chief Financial Officer	2305 WASHINGTON STREET, APT 301, SAN FRANCISCO CA 94115
Chirinjeev Kathuria	director	C/O UPHEALTH HOLDINGS, INC., 14000 S. MILITARY TRAIL #203, DELRAY BEACH FL 33484
Jerome Ringo	director	1731 EMBARCADERO ROAD SUITE 200, PALO ALTO CA 94303
Poseidon Bio, Llc	10 percent owner	OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Daniel Behr	officer: EVP, Innov./Acad. P'ships Head	OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Jack A Elias	director	OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Jonathan Kurtis	director	OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Elizabeth Ng	director, officer: Chief Executive Officer	OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Martin D Angle	director	OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Aesther Healthcare Sponsor, Llc	10 percent owner	515 MADISON AVE., SUITE 8078, NEW YORK NY 10022
Michael L Peterson	director	17 CANARY COURT, DANVILLE CA 94526